Home › Research › Drug development
Effect and mechanism of GLP-1 on cognitive function in diabetes mellitus
Dou X, Zhao L, Li J, Jiang Y.. Frontiers in neuroscience, 2025-03-18
Topic: Brain proteins, microglia and lab models
Background Diabetes mellitus (DM) is a metabolic disorder associated with cognitive impairment. Glucagon-like peptide-1 (GLP-1) and its receptor (GLP-1R) have shown neuroprotective effects. Scope of review This review explores the impact of DM on cognitive function. Diabetes-related cognitive impairment is divided into three stages: diabetes-associated cognitive decrements, mild cognitive impairment (MCI), and dementia. GLP-1R agonists (GLP-1RAs) have many functions, such as neuroprotection, inhibiting infection, and metabolic regulation, and show good application prospects in improving cognitive function. The mechanisms of GLP-1RAs neuroprotection may be interconnected, warranting further investigation. Understanding these mechanisms could lead to targeted treatments for diabetes-related cognitive dysfunction. Major conclusions Therefore, this paper reviewed the regulatory effects of GLP-1 on cognitive dysfunction and its possible mechanism. Further research is required to fully explore the potential of GLP-1 and its analogs in this context.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Dou, X., Zhao, L., Li, J., & Jiang, Y. (2025). Effect and mechanism of GLP-1 on cognitive function in diabetes mellitus. Frontiers in neuroscience. https://doi.org/10.3389/fnins.2025.1537898
Vancouver
Dou X, Zhao L, Li J, Jiang Y. Effect and mechanism of GLP-1 on cognitive function in diabetes mellitus. Frontiers in neuroscience. 2025. doi:10.3389/fnins.2025.1537898. PMID: 40171533.
BibTeX
@article{dou2025-40171533,
author = {Dou, X. and Zhao, L. and Li, J. and Jiang, Y.},
title = {{Effect and mechanism of GLP-1 on cognitive function in diabetes mellitus}},
journal = {Frontiers in neuroscience},
year = {2025},
doi = {10.3389/fnins.2025.1537898},
pmid = {40171533},
url = {https://doi.org/10.3389/fnins.2025.1537898}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Background Diabetes mellitus (DM) is a metabolic disorder associated with cognitive impairment.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 45/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 26 of the 58 points we could judge it on, which is 45 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in neuroscience) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40171533) |
| Free to read | 2 / 2 | Free to read |
| Points | 26 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 26 of the 58 points we could judge it on is 45 out of 100. |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development
Also tagged “mechanisms”
5 studies in the library carry the topic tag “mechanisms”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 5 tagged studies.